September 19, 2024
Saudi Snapshot
PR Newswire

Sceye Secures Funds in Series C Round Led by Mawarid Holding Company

Sceye Valued at $525 Million and Poised for 2025 Commercial Launch 

PARIS, Sept. 17, 2024 /PRNewswire/ — At World Space Business Week (WSBW) today, Sceye, a leading U.S. aerospace company specializing in High-Altitude Platform Systems (HAPS), announced the successful closing of its Series C funding round. The round was led by Mawarid Holding Company (“Mawarid”), a prominent Saudi corporation with an established presence in information and communication technology, satellite, and digital solutions.

Test flight from November 2023

Sceye strengthened its balance sheet by closing the Series C funding round, which values the Company at a pre-money valuation of $525 million. This provides sufficient liquidity to fund R&D activities, flight programs and launch the initial commercial operations in 2025.

This strategic alliance continues Sceye’s successful partnership strategy, following América Móvil’s involvement as the largest investor in their Series B round with a focus on Latin America.

“The Series C round is a critical milestone for Sceye. These funds will accelerate our platform development and commercial roadmap, paving the way for the commercialization of our HAPS technology in 2025. Our partnership with Mawarid opens new territories and market opportunities for our innovative solutions,” said Mikkel Vestergaard Frandsen, CEO and Founder of Sceye.

Ghassan Itani, Assistant Chairman of Mawarid, added, “This partnership reinforces Mawarid’s commitment to pioneering technology advancements and delivering digital solutions that serve critical industry sectors. By incorporating HAPS technology, we enhance our position as a comprehensive provider of strategic industry solutions.”

This Series C investment announcement follows the success of Sceye’s 2024 flight program, where the company achieved a significant milestone by demonstrating perpetual flight capabilities while staying over an area of operation. The test flight proved that Sceye’s HAPS can operate continuously, with solar energy powering the system during daylight hours and battery storage ensuring overnight flight.

This achievement signifies the advent of a new infrastructure layer between terrestrial and space systems. It highlights the transformative potential of HAPS technology in expanding connectivity access, managing disaster response, monitoring environmental changes, and detecting climate-related disasters in real time.

About Sceye
Founded in 2014, Sceye is an aerospace company dedicated to advancing stratospheric technology to connect people and protect the planet. Sceye leads the High-Altitude Platform Systems (HAPS) industry, focusing on universal connectivity, climate monitoring, natural resource management, and disaster prevention.

About Mawarid:
Established in 1968, Mawarid Holding Company (MHC) is a leading Saudi corporation with a diverse portfolio spanning, but not limited to,  ICT, satellite, and digital solutions. MHC has been a player in the global communications landscape, including its role as a founder and shareholder in Iridium Communications Inc. (Nasdaq: IRDM) since the early 1990s and its operations in various ICT and media sectors across the Middle East (e.g., Salam, TLS, ATSS, “Noorsat: Geo-operator”).

Media Contact:
Jasmine Wallsmith
jw@sceye.com

Photo – https://mma.prnewswire.com/media/2506000/AD6_Wide.jpg
Logo – https://mma.prnewswire.com/media/2484213/sceye_logo_suitcase_logo_full_colour_rgb_1000px_72ppi_ID_a12cb870d06f_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/sceye-secures-funds-in-series-c-round-led-by-mawarid-holding-company-302248799.html

Related posts

Ahead of COP27 Energy Day, African Forests in Crosshairs of Oil and Gas Expansion: A Threat Facing Ecosystems and Communities Globally

Admin

Abu Dhabi Islamic Bank increases ownership in ADIB Egypt to over 52 percent

Admin

Servier’s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)

Admin